Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 

4-Traders Homepage  >  Equities  >  Nyse MKT  >  ImmunoCellular Therapeutics Ltd    IMUC

Delayed Quote. Delayed  - 07/26 09:42:01 pm
0.2123 USD   +0.57%
07/25 IMMUNOCELLULAR : Reports Progress in Two Lead Cancer Immunotherapy ..
06/07 IMMUNOCELLULAR : Treats First Patient in ICT-107 Phase 3 Registrati..
05/23 IMMUNOCELLULAR : to Present at Marcum MicroCap Conference on June 2..
 SummaryQuotesChartsNewsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Nyse Mkt
07/20/2016 07/21/2016 07/22/2016 07/25/2016 07/26/2016 Date
0.2005(c) 0.209(c) 0.208(c) 0.2111(c) 0.2123 Last
1 127 005 879 165 357 190 866 719 538 512 Volume
-5.25% +4.24% -0.48% +1.49% +0.57% Change
More quotes
Financials ($)
Sales 2016 -
EBIT 2016 -24,8 M
Net income 2016 -25,8 M
Debt 2016 -
Yield 2016 -
Sales 2017 -
EBIT 2017 -26,3 M
Net income 2017 -27,4 M
Debt 2017 -
Yield 2017 -
P/E ratio 2016 -
P/E ratio 2017
Capi. / Sales2016 0
Capi. / Sales2017 0
Capitalization 19,7 M
More Financials
Company
ImmunoCellular Therapeutics Ltd. is a Los Angeles-based clinical-stage company that develops immune-based therapies for the treatment of brain and other cancers.ImmunoCellular's pipeline includes: ICT-121, a dendritic cell immunotherapy targeting the CD133 antigen on stem cells in recurrent... 
More about the company
Latest news on IMMUNOCELLULAR THERAPEUTIC
07/25 IMMUNOCELLULAR THERAPEUTICS : Reports Progress in Two Lead Cancer Immunotherapy ..
06/21 IMMUNOCELLULAR THERAPEUTICS, LTD. : Submission of Matters to a Vote of Security ..
06/16 IMMUNOCELLULAR THERAPEUTICS : Treats First Patient in ICT-107 Phase 3 Registrati..
06/07 IMMUNOCELLULAR THERAPEUTICS, LTD. : Other Events (form 8-K)
06/07 IMMUNOCELLULAR THERAPEUTICS : Treats First Patient in ICT-107 Phase 3 Registrati..
05/23 IMMUNOCELLULAR THERAPEUTICS : to Present at Marcum MicroCap Conference on June 2..
05/19 IMMUNOCELLULAR THERAPEUTICS : Announces First Quarter 2016 Financial Results
05/19 IMMUNOCELLULAR THERAPEUTICS : BioLife Solutions and MNX Global Logistics Partner..
05/13 IMMUNOCELLULAR THERAPEUTICS : Management's Discussion and Analysis of Financial ..
05/12 IMMUNOCELLULAR THERAPEUTICS, LTD. : Results of Operations and Financial Conditio..
More news
Sector news : Biotechnology & Medical Research - NEC
12:45a GILEAD SCIENCES : cuts 2016 sales forecast, cites hepatitis C drugs
07/25DJGILEAD SCIENCES : Sales of Hepatitis C Drugs Fall 19% -- 2nd Update
07/25DJCELGENE : Drug Misses Secondary Endpoint in One of Its Lymphoma Trials
07/25DJGILEAD SCIENCES : Sales of Hepatitis C Drugs Fall 19% -- 3rd Update
07/25DJGILEAD SCIENCES : Sales of Hepatitis C Drugs Fall 19% -- Update
More sector news : Biotechnology & Medical Research - NEC
News from SeekingAlpha
06/07 ImmunoCellular's late-stage study of lead product candidate in glioblastoma c..
05/12 ImmunoCellular Therapeutics' (IMUC) CEO Andrew Gengos on Q1 2016 Results - Ea..
05/12 ImmunoCellular Therapeutics beats by $0.01
03/31 ImmunoCellular Therapeutics' (IMUC) CEO Andrew Gengos on Q4 2015 Results - Ea..
03/31 ImmunoCellular Therapeutics reports FY15 results
Advertisement
Chart IMMUNOCELLULAR THERAPEUTIC
Duration : Period :
ImmunoCellular Therapeutic Technical Analysis Chart | IMUC | US4525361055 | 4-Traders
Full-screen chart
Income Statement Evolution
More Financials
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 2
Average target price 2,50 $
Spread / Average Target 1 084%
Consensus details
EPS Revisions
More Estimates Revisions
Managers
NameTitle
Andrew Gengos President, Chief Executive Officer & Director
Gary S. Titus Chairman
David E. Fractor Principal Financial & Accounting Officer
Steven J. Swanson Senior Vice President-Research
John S. Yu Secretary & Director
More about the company
Sector and Competitors
1st jan.Capitalization (M$)
IMMUNOCELLULAR THERAPE..-41.46%20
INCYTE CORPORATION-20.30%16 216
CELLTRION, INC.--.--%10 681
LONZA GROUP AG11.40%9 730
QUINTILES TRANSNATIONA..7.89%8 865
ALKERMES PLC-36.86%7 576
More Results